Has Jon Kobashigawa, MD received payments from drug or device companies?

Yes. Drug and device makers reported $54,290 in general payments to Jon Kobashigawa, MD across 31 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jon Kobashigawa, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jon Kobashigawa, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jon Kobashigawa, MD

Advanced Heart Failure and Transplant Cardiology · Los Angeles, CANPI 1467548073

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $42,363 of the $54,290 with a category attached, or 78.0%. 9 manufacturers reported payments, led by Transmedics, Inc. at 55.3% of the total. Reporting peaked in 2021 at $40,863 and has fallen 100.0% since, to $16 in 2025.

$54,290in general payments, 2019–2025

Across 31 payments — averaging $1751.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Transmedics, Inc.$30K
Sanofi-aventis U.S. LLC$19K
One Lambda, Inc.$2K
Merck$2K
Paragonix Technologies, Inc.$2K
Abbott$113
plus $106 from 3 others

$499,476in research payments, 2019–2025

Across 9 payments — averaging $55,497 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Sanofi-aventis U.S. LLC$406K
Sanofi$78K
Transmedics, Inc.$15K

What the payments were for

Consulting fees$42,36378%
Speaking & faculty fees$9,88318%
Travel & lodging$1,5473%
Food & beverage$4971%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Transmedics, Inc.	9	$30,000
Sanofi-aventis U.S. LLC	9	$19,279
One Lambda, Inc.	2	$1,662
Merck	4	$1,631
Paragonix Technologies, Inc.	1	$1,500
Abbott	1	$113
Takeda Pharmaceuticals U.S.A., Inc.	3	$72
Gilead	1	$18
E.r. Squibb & Sons, L.L.C.	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$54,290 in reported general payments places this provider in the 70th percentile of 111 advanced heart failure and transplant cardiology providers in California.

See all advanced heart failure and transplant cardiology providers in California →

Medicare billing

Part B allowed, 2024

$91,685

Medicare patients

352

Services billed

1,145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
VyndaqelTafamidis Meglumine	12	$270,149
EliquisApixaban	107	$99,418
XareltoRivaroxaban	56	$75,596
EntrestoSacubitril/Valsartan	50	$50,506
JardianceEmpagliflozin	32	$44,466
Repatha SureclickEvolocumab	15	$21,595
Repatha PushtronexEvolocumab	16	$15,283
Valganciclovir Hcl	40	$6,691
Diovan HctValsartan/Hydrochlorothiazide	12	$5,168
Ranolazine ErRanolazine	30	$2,982
Tacrolimus	20	$2,878
Metoprolol Succinate	147	$2,615
Nebivolol Hcl	24	$2,321
Nifedipine ErNifedipine	34	$2,287
Losartan Potassium	95	$1,741

Paid to pharmacies, not to this prescriber.

Other advanced heart failure and transplant cardiology in Los Angeles

Eugene DepasqualeLos Angeles$104K
Joseph RahmanLos Angeles$101K
Ajay VaidyaLos Angeles$17K
Aaron WolfsonLos Angeles$16K
Michael FongLos Angeles$9K
Richard WrightSanta Monica$1.7M
James Heywoodla Jolla$1.2M
Hirsch MehtaSan Diego$494K
Teresa de MarcoSan Francisco$366K
Rajeev Mohanla Jolla$357K

See the full list for California →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →